At the same time, new data on retatrutide shows powerful results for people with type 2 diabetes, while drug companies are already developing next-generation therapies beyond GLP-1s
Lu L, Wang JR, Henderson YC, Bai S Yang J, Hu M, Shiau CK, Pan TY, Yan Y, Tran TM, Li J, Kieser R, Zhao X, Wang J, r N, Williams MD, Cabanillas ME, Dadu R, Busaidy N, Zafereo ME , Navin N, Lai SY, Gao R
By Route of Administration The parenteral segment is expected to register a CAGR of 13.31% during the forecast period, due to established once weekly injectable formulations offering high bioavailability, consistent therapeutic performance, and availability of advanced pen delivery systems that improve dosing accuracy
NO reacts with superoxide anion (O 2 ) to form a stronger oxidant identified as peroxynitrite anion (ONOO )